Lord's Mark Industries and IIT Bombay Partner to Transform Sickle Cell Testing in India with Point of Screening Technology

 by Priya Jadhav

MUMBAI, 25^th May 2023

To be the exclusive production and distribution partner of the patented IITB, IP “Shape DX”-equipped sickle cell testing equipment 

To collaborate with the Central Government and Social Organizations to make the Sickle Cell Testing POS (point of screening) equipment available at Government healthcare centers, labs, and hospitals. 

To launch 1000 pathology labs across India for sickle cell testing and other healthcare services, with an initial investment of Rs. 50 crores. Lord’s Mark Industries is into development of various kind of patient friendly IVD, Hematology and serology products which will give highly accurate results to the tune of 100% 

Lord’s Mark Industries, through its subsidiary Lord’s Mark Biotech will take this screening to Gynecologists and obstetricians across the country for early detection pre and post pregnancy. Lord’s Mark Biotech is already present in the Women’s wellness therapy area through a dedicated team of 200 sales professionals to accelerate this testing and screening at the point of care. 

Lord’s Mark Biotech is embarking into alliances with Global Research companies to bring patented products in difficult to treat conditions of Joint care, Kidney care, chronic skincare diseases and many more in times to come. Lord’s Mark Biotech is launching a plethora of Products in women’s health and lifestyle segment for healthy living in aging population which will positively impact a large segment of Indian population.

Lord's Mark Industries, a prominent diversified business group, has partnered with the renowned Indian Institute of Technology Bombay (IIT-B) to revolutionize sickle cell testing in India. The first-ever AI-enabled POS equipment in the country, patented by IIT Bombay, will address challenges associated with sickle cell testing, making it more accessible and convenient with 100% accuracy. The announcement was made at a conference in Intercontinental Hotel, Mumbai. Lord's Mark Industries will invest Rs 25 crores to develop and distribute the technology-enabled POS equipment, targeting revenue of Rs 100 crores by year 2026-27.

Lord's Mark Industries will use its in-house R&D team to manufacture the sickle cell POS instrument at its IVD manufacturing facility in Vasai. The equipment will be available in government healthcare centers, pathology labs, and Lord's Mark Industries' pathology labs throughout the country.

Commenting on the collaboration, Mr. Sachidanand Upadhyay, Founder, Lord’s Mark Industries said, "Through this collaboration with IIT-B, Lord's Mark Industries is committed to providing innovative and effective solutions to sickle cell testing across India, especially in rural regions. We are also investing in the establishment of 1000 pathology labs across the country, with an initial investment of Rs. 50 crores, to provide easy access to sickle cell testing and other healthcare services. With the support of the Central Government, we aim to make equipment and testing available across government healthcare centers and hospitals.”

The microscopy-based test developed by renowned Prof. Debjani Paul and her team from the Dept. of Biosciences & Bioengineering at IIT-B can distinguish between healthy, sickle trait, and sickle anemia blood samples at the point of care. The collaboration between IIT-B and Lord's Mark Industries aims to revolutionize sickle cell testing in India, providing improved disease diagnosis and management for patients across the country at the point of primary care itself thereby reducing costs and enabling a convenience for affected population. This is the only microscopy test that can actually distinguish carriers from individual who have sickle anemia within 30 minutes. Typically it would take 24 – 48 hours to identify the carriers.

"We are excited to collaborate with Lord's Mark Industries to introduce our Licensed AI-enabled sickle cell testing technology in India. Our technology is a game changer in tackling sickle cell screening challenges in the affected regions. We believe that our technology combined with Lord's Mark Industries capabilities will make a significant impact on improving the lives of millions of patients suffering from sickle cell anemia in the country," said Dr. Oshin Sharma, Researcher, IIT Bombay.

The Indian government has taken measures to improve sickle cell anemia detection and treatment in central and southern regions such as Gujarat, Maharashtra, Chhattisgarh, Orissa, Bengal, Tamil Nadu, Kerala, and Telangana. Measures include newborn screening, a national eradication campaign, clinical trials, and premarital counseling protocols. The Ministry of Tribal Affairs has circulated advisories, and Rs. 60 crores has been released to the States seeking grants to tackle the disease, including screening.

In line with these efforts, the partnership between Lord's Mark Industries and IIT Bombay is a significant step towards combating sickle cell disease in India. The collaboration aims to improve the screening and diagnosis process, making it more accessible and convenient for patients. This will promote early intervention and improve disease management, contributing to the efforts of the Indian government to eradicate the disease.

About Lord’s Mark Industries: Lord’s Mark Industries with its business verticals in diagnostics, hygiene care and biotech/pharmaceuticals has a deep knowledge of testing and screening. The company is desirous of manufacturing and commercializing the point of care for Sickle cell test for healthcare and diagnostics application using Licensed IP from IIT Mumbai.

Lord's Mark Industries has been delivering value to all stakeholders and partners by creating sustainable business to become a globally recognized brand in diversified industries. Incorporated in 1998, Lord’s Mark Industries Private Ltd. (Lord’s) started manufacturing computer continuous stationery and copier paper and slowly diversified to other segments viz; LED products, Solar Power Solutions & Solar Appliances, Lithium Batteries, Electric Scooters, Charging Stations apart from the diagnostics and Biotech/Pharmaceuticals.